The BH3-only protein BimL overrides Bcl-2-mediated apoptosis resistance in melanoma cells

Cancer Letters

Volumn 335, Issue 1, 2013, Pages 100-108

  Plötz, Michael ^a   Gillissen, Bernhard ^a   Quast, Sandra Annika ^a   Berger, Anja ^a   Daniel, Peter T ^a   Eberle, Jürgen ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Apoptosis; Bcl 2; BimL; Melanoma; Mitochondria

Indexed keywords

ADENOVIRUS VECTOR; ANTIBODY; BIM PROTEIN; CASPASE 9; COMPLEMENTARY DNA; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN BCL XL; PROTEIN MCL 1; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; BAK GENE; BAX GENE; BCL 2 GENE; CANCER RESISTANCE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME RELEASE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MELANOMA CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CASPASE 9; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; GENE EXPRESSION; HUMANS; MELANOMA; MEMBRANE PROTEINS; MITOCHONDRIA; PROTEIN BINDING; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84878433605     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.02.005     Document Type: Article

References (57)

1. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
2. Eberle J., Kurbanov B.M., Hossini A.M., Trefzer U., Fecker L.F. Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches. Drug Resistance Updates 2007, 10:218-234.
3. Garbe C., Leiter U. Melanoma epidemiology and trends. Clinics in Dermatology 2009, 27:3-9.
4. Krammer P.H., Arnold R., Lavrik I.N. Life and death in peripheral T cells. Nature Reviews Immunology 2007, 7:532-542.
5. Bilim V., Yuuki K., Itoi T., Muto A., Kato T., Nagaoka A., Motoyama T., Tomita Y. Double inhibition of XIAP and Bcl-2 axis is beneficial for retrieving sensitivity of renal cell cancer to apoptosis. British Journal of Cancer 2008, 98:941-949.
6. Chipuk J.E., Moldoveanu T., Llambi F., Parsons M.J., Green D.R. The BCL-2 family reunion. Molecular Cell 2010, 37:299-310.
7. van Delft M.F., Huang D.C. How the Bcl-2 family of proteins interact to regulate apoptosis. Cell Research 2006, 16:203-213.
8. Hossini A.M., Eberle J. Apoptosis induction by Bcl-2 proteins independent of the BH3 domain. Biochemical Pharmacology 2008, 76:1612-1619.
9. Willis S.N., Adams J.M. Life in the balance: how BH3-only proteins induce apoptosis. Current Opinion in Cell Biology 2005, 17:617-625.
10. Gallenne T., Gautier F., Oliver L., Hervouet E., Noel B., Hickman J.A., Geneste O., Cartron P.F., Vallette F.M., Manon S., Juin P. Bax activation by the BH3-only protein Puma promotes cell dependence on antiapoptotic Bcl-2 family members. Journal of Cell Biology 2009, 185:279-290.
11. Jansen B., Wacheck V., Heere-Ress E., Schlagbauer-Wadl H., Hoeller C., Lucas T., Hoermann M., Hollenstein U., Wolff K., Pehamberger H. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 2000, 356:1728-1733.
12. Eberle J., Hossini A.M. Expression and function of bcl-2 proteins in melanoma. Current Genomics 2008, 9:409-419.
13. Akgul C., Moulding D.A., Edwards S.W. Alternative splicing of Bcl-2-related genes: functional consequences and potential therapeutic applications. Cellular and Molecular Life Sciences 2004, 61:2189-2199.
14. Eberle J., Fecker L.F., Hossini A.M., Wieder T., Daniel P.T., Orfanos C.E., Geilen C.C. CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants. Oncogene 2003, 22:9131-9141.
15. Raisova M., Hossini A.M., Eberle J., Riebeling C., Wieder T., Sturm I., Daniel P.T., Orfanos C.E., Geilen C.C. The Bax/Bcl-2 ratio determines the susceptibility of human melanoma cells to CD95/Fas-mediated apoptosis. Journal of Investigative Dermatology 2001, 117:333-340.
16. Gillissen B., Essmann F., Hemmati P.G., Richter A., Richter A., Oztop I., Chinnadurai G., Dorken B., Daniel P.T. Mcl-1 determines the Bax dependency of Nbk/Bik-induced apoptosis. Journal of Cell Biology 2007, 179:701-715.
17. Eberle J., Weitmann S., Thieck O., Pech H., Paul M., Orfanos C.E. Downregulation of endothelin B receptor in human melanoma cell lines parallel to differentiation genes. Journal of Investigative Dermatology 1999, 112:925-932.
18. Miyashita M.U.T., Shikama Y., Tadokoro K., Yamada M. Molecular cloning and characterization of six novel isoforms of human Bim, a member of the proapoptotic Bcl-2 family. FEBS Letters 2001, 509:135-141.
19. Gillissen B., Essmann F., Graupner V., Starck L., Radetzki S., Dorken B., Schulze-Osthoff K., Daniel P.T. Induction of cell death by the BH3-only Bcl-2 homolog Nbk/Bik is mediated by an entirely Bax-dependent mitochondrial pathway. EMBO Journal 2003, 22:3580-3590.
20. Plötz M., Gillissen B., Hossini A.M., Daniel P.T., Eberle J. Disruption of the VDAC2-Bak interaction by Bcl-x(S) mediates efficient induction of apoptosis in melanoma cells. Cell Death and Differentiation 2012, 19:1928-1938.
21. Riccardi C., Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nature Protocols 2006, 1:1458-1461.
22. Martinou J.C., Youle R.J. Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. Developmental Cell 2011, 21:92-101.
23. Kurbanov B.M., Geilen C.C., Fecker L.F., Orfanos C.E., Eberle J. Efficient TRAIL-R1/DR4-mediated apoptosis in melanoma cells by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Journal of Investigative Dermatology 2005, 125:1010-1019.
24. Franke J.C., Plötz M., Prokop A., Geilen C.C., Schmalz H.G., Eberle J. New caspase-independent but ROS-dependent apoptosis pathways are targeted in melanoma cells by an iron-containing cytosine analogue. Biochemical Pharmacology 2010, 79:575-586.
25. Soengas M.S., Lowe S.W. Apoptosis and melanoma chemoresistance. Oncogene 2003, 22:3138-3151.
26. Braun F.K., Fecker L.F., Schwarz C., Walden P., Assaf C., Durkop H., Sterry W., Eberle J. Blockade of death receptor-mediated pathways early in the signaling cascade coincides with distinct apoptosis resistance in cutaneous T-cell lymphoma cells. Journal of Investigative Dermatology 2007, 127:2425-2437.
27. O'Reilly L.A., Cullen L., Visvader J., Lindeman G.J., Print C., Bath M.L., Huang D.C.S., Strasser A. The proapoptotic BH3-only protein bim is expressed in hematopoietic, epithelial, neuronal, and germ cells. American Journal of Pathology 2000, 157:449-461.
28. Pinon J.D., Labi V., Egle A., Villunger A. Bim and Bmf in tissue homeostasis and malignant disease. Oncogene 2008, 27:S41-S52.
29. Zantl N., Weirich G., Zall H., Seiffert B.M., Fischer S.F., Kirschnek S., Hartmann C., Fritsch R.M., Gillissen B., Daniel P.T., Hacker G. Frequent loss of expression of the pro-apoptotic protein Bim in renal cell carcinoma: evidence for contribution to apoptosis resistance. Oncogene 2007, 26:7038-7048.
30. Dai D.L., Wang Y.M., Liu M., Martinka M., Li G. Bim expression is reduced in human cutaneous melanomas. Journal of Investigative Dermatology 2008, 128:403-407.
31. Akiyama T., Dass C.R., Choong P.F.M. Bim-targeted cancer therapy: a link between drug action and underlying molecular changes. Molecular Cancer Therapeutics 2009, 8:3173-3180.
32. Hossini A.M., Eberle J., Fecker L.F., Orfanos C.E., Geilen C.C. Conditional expression of exogenous Bcl-X(S) triggers apoptosis in human melanoma cells in vitro and delays growth of melanoma xenografts. FEBS Letters 2003, 553:250-256.
33. Oppermann M., Geilen C.C., Fecker L.F., Gillissen B., Daniel P.T., Eberle J. Caspase-independent induction of apoptosis in human melanoma cells by the proapoptotic Bcl-2-related protein Nbk/Bik. Oncogene 2005, 24:7369-7380.
34. Plötz M., Hossini A.M., Daniel P.T., Stockfleth E., Eberle J. Mutual regulation of Bcl-2 proteins independent of the BH3 domain as shown by the BH3-lacking protein Bcl-xAK. PLoS ONE 2012, 7:e34549.
35. Lindenboim L., Kringel S., Braun T., Borner C., Stein R. Bak but not Bax is essential for Bcl-xS-induced apoptosis. Cell Death and Differentiation 2005, 12:713-723.
36. Adams J.M., Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007, 26:1324-1337.
37. Llambi F., Green D.R. Apoptosis and oncogenesis: give and take in the BCL-2 family. Current Opinion in Genetics & Development 2011, 21:12-20.
38. Fecker L.F., Geilen C.C., Tchernev G., Trefzer U., Assaf C., Kurbanov B.M., Schwarz C., Daniel P.T., Eberle J. Loss of proapoptotic Bcl-2-related multidomain proteins in primary melanomas is associated with poor prognosis. Journal of Investigative Dermatology 2006, 126:1366-1371.
39. Nehls O., Okech T., Hsieh C.J., Enzinger T., Sarbia M., Borchard F., Gruenagel H.H., Gaco V., Hass H.G., Arkenau H.T., Hartmann J.T., Porschen R., Gregor M., Klump B. Studies on p53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: major prognostic impact of proapoptotic BAX. British Journal of Cancer 2007, 96:1409-1418.
40. Mcgill G.G., Horstmann M., Widlund H.R., Du J.Y., Motyckova G., Nishimura E.K., Lin Y.L., Ramaswamy S., Avery W., Ding H.F., Jordan S.A., Jackson I.J., Korsmeyer S.J., Golub T.R., Fisher D.E. Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 2002, 109:707-718.
41. Bedikian A.Y., Millward M., Pehamberger H., Conry R., Gore M., Trefzer U., Pavlick A.C., DeConti R., Hersh E.M., Hersey P., Kirkwood J.M., Haluska F.G. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the oblimersen melanoma study group. Journal of Clinical Oncology 2006, 24:4738-4745.
42. Zhuang L.Q., Lee C.S., Scolyer R.A., McCarthy S.W., Zhang X.D., Thompson J.F., Hersey P. Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Modern Pathology 2007, 20:416-426.
43. Senft D., Berking C., Graf S.A., Kammerbauer C., Ruzicka T., Besch R. Selective induction of cell death in melanoma cell lines through targeting of Mcl-1 and A1. PLoS ONE 2012, 7:e30821.
44. Weber A., Paschen S.A., Heger K., Wilfling F., Frankenberg T., Bauerschmitt H., Seiffert B.M., Kirschnek S., Wagner H., Hacker G. BimS-induced apoptosis requires mitochondrial localization but not interaction with anti-apoptotic Bcl-2 proteins. Journal of Cell Biology 2007, 177:625-636.
45. Youle R.J., Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nature Reviews Molecular Cell Biology 2008, 9:47-59.
46. Yan W., Samson M., Jegou B., Toppari J. Bcl-w forms complexes with Bax and Bak, and elevated ratios of Bax/Bcl-w and Bak/Bcl-w correspond to spermatogonial and spermatocyte apoptosis in the testis. Molecular Endocrinology 2000, 14:682-699.
47. Willis S.N., Chen L., Dewson G., Wei A., Naik E., Fletcher J.I., Adams J.M., Huang D.C. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes & Development 2005, 19:1294-1305.
48. Chen L., Willis S.N., Wei A., Smith B.J., Fletcher J.I., Hinds M.G., Colman P.M., Day C.L., Adams J.M., Huang D.C. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Molecular Cell 2005, 17:393-403.
49. Fecker L.F., Ruckert S., Kurbanov B.M., Schmude M., Stockfleth E., Fechner H., Eberle J. Efficient melanoma cell killing and reduced melanoma growth in mice by a selective replicating adenovirus armed with tumor necrosis factor-related apoptosis-inducing ligand. Human Gene Therapy 2011, 22:405-417.
50. C. Billard, Design of Novel BH3 Mimetics for the Treatment of Chronic Lymphocytic Leukemia, Leukemia Epub ahead of print, 2012, doi: . doi:10.1038/leu.2012.88.
51. Xiao C.C., Srinivasan L., Calado D.P., Patterson H.C., Zhang B.C., Wang J., Henderson J.M., Kutok J.L., Rajewsky K. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nature Immunology 2008, 9:405-414.
52. Zhang Z.C., Song T., Zhang T.T., Gao J., Wu G.Y., An L.J., Du G.H. A novel BH3 mimetic S1 potently induces Bax/Bak-dependent apoptosis by targeting both Bcl-2 and Mcl-1. International Journal of Cancer 2011, 128:1724-1735.
53. Cartlidge R.A., Thomas G.R., Cagnol S., Jong K.A., Molton S.A., Finch A.J., McMahon M. Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival. Pigment Cell and Melanoma Research 2008, 21:534-544.
54. Sosman J.A., Kim K.B., Schuchter L., Gonzalez R., Pavlick A.C., Weber J.S., McArthur G.A., Hutson T.E., Moschos S.J., Flaherty K.T., Hersey P., Kefford R., Lawrence D., Puzanov I., Lewis K.D., Amaravadi R.K., Chmielowski B., Lawrence H.J., Shyr Y., Ye F., Li J., Nolop K.B., Lee R.J., Joe A.K., Ribas A. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. New England Journal of Medicine 2012, 366:707-714.
55. Ewings K.E., Wiggins C.M., Cook S.J. Bim and the pro-survival Bcl-2 proteins: opposites attract, ERK repels. Cell Cycle 2007, 6:2236-2240.
56. Hendrickson A.W., Meng X.W., Kaufmann S.H. Anticancer therapy: boosting the bang of Bim. Journal of Clinical Investigation 2008, 118:3582-3584.
57. Jiang C.C., Lai F., Tay K.H., Croft A., Rizos H., Becker T.M., Yang F., Liu H., Thorne R.F., Hersey P., Zhang X.D. Apoptosis of human melanoma cells induced by inhibition of B-RAF(V600E) involves preferential splicing of bim(S). Cell Death and Disease 2010, 1.